Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 81 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The comparison between long acting insulin analogues (LAIA) and human insulin (NPH) has been investigated for decades, with many randomized controlled trials (RCTs) and systematic reviews giving mixed results. This overlapping and contradictory evidence has increased uncertainty on coverage decisions at health systems level. AIM: To conduct an overview of systematic reviews and update existing reviews, preparing new meta-analysis to determine whether LAIA are effective for T1D patients compared to NPH. METHODS: We identified systematic reviews of RCTs that evaluated the efficacy of LAIA glargine or detemir, compared to NPH insulin for T1D, assessing glycated hemoglobin (A1C) and hypoglycemia. Data sources included Pubmed, Cochrane Library, EMBASE and hand-searching. The methodological quality of studies was independently assessed by two reviewers, using AMSTAR and Jadad scale. We found 11 eligible systematic reviews that contained a total of 25 relevant clinical trials. Two reviewers independently abstracted data. RESULTS: We found evidence that LAIA are efficacious compared to NPH, with estimates showing a reduction in nocturnal hypoglycemia episodes (RR 0.66; 95% CI 0.57; 0.76) and A1C (95% CI 0.23; 0.12). No significance was found related to severe hypoglycemia (RR 0.94; 95% CI 0.71; 1.24). CONCLUSION: This study design has allowed us to carry out the most comprehensive assessment of RCTs on this subject, filling a gap in diabetes research. Our paper addresses a question that is important not only for decision makers but also for clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Regardless of the insulin delivery method (MDI vs CSII), glycemic control metrics, including A1C and CGM TIR, hypoglycemic events, QoL, and patient satisfaction are substantially improved when MDI or CSII is augmented with CGM, with better results when CSII is combined with CGM or integrated into AID systems, compared with using CGM.158,160,1129–1131”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
Kirkwood, B. R., & Sterne, J. A. C. (2014) · Bristol Research (University of Bristol) · Cited by 2,820
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
(2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.118887 · Cited by 460
Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455
Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
Development, feasibility and performance of a health risk appraisal questionnaire for older persons
Stuck, A. E., Kharicha, K., Dapp, U., Anders, J., von Renteln-Kruse, W., Meier-Baumgartner, H. P., Harari, D., Swift, C. G., Ivanova, K., Egger, M., et al. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-1 · Cited by 324
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
Home, P., Bartley, P., Russell-Jones, D., Hanaire-Broutin, H., Heeg, J.-E., Abrams, P., Landin-Olsson, M., Hylleberg, B., Lang, H., Draeger, E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1081 · Cited by 254
Raskin, P., Klaff, L., Bergenstal, R., Hallé, J. P., Donley, D., & Mecca, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1666 · Cited by 250
Establishing a new journal for systematic review products
Moher, D., Stewart, L., & Shekelle, P. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-1 · Cited by 245
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 243
Pieber, T. R., Eugène-Jolchine, I., & Derobert, E. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.157 · Cited by 224
Rosenstock, J., Park, G., Zimmerman, J., & U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1137 · Cited by 196
Pollock, M., Fernandes, R. M., Becker, L. A., Featherstone, R., & Hartling, L. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0367-5 · Cited by 195
Russell-Jones, D., Simpson, R., Hylleberg, B., Draeger, E., & Bolinder, J. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90072-0 · Cited by 194
Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin
Hermansen, K., Madsbad, S., Perrild, H., Kristensen, A., & Axelsen, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.296 · Cited by 174
Murphy, N. P., Keane, S. M., Ong, K. K., Ford-Adams, M., Edge, J. A., Acerini, C. L., & Dunger, D. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.799 · Cited by 163
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159
Mullins, P. R., Sharplin, P., Yki‐Järvinen, H., Riddle, M. C., & Häring, H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.020 · Cited by 156
Insulin glargine: A systematic review of a long-acting insulin analogue
Wang, F., Carabino, J. M., & Vergara, C. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80156-x · Cited by 154
Rossetti, P., Pampanelli, S., Fanelli, C., Porcellati, F., Costa, E., Torlone, E., Scionti, L., & Bolli, G. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1490 · Cited by 151
Assessment and management of hypoglycemia in children and adolescents with diabetes
Ly, T. T., Maahs, D. M., Rewers, A., Dunger, D., Oduwole, A., & Jones, T. W. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12174 · Cited by 151
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
Robertson, K. J., Schoenle, E., Gucev, Z., Mordhorst, L., Gall, M. ‐., & Ludvigsson, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02024.x · Cited by 149
Cheung, A., Weir, M., Mayhew, A., Kozloff, N., Brown, K., & Grimshaw, J. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-36 · Cited by 141
Porcellati, F., Rossetti, P., Pampanelli, S., Fanelli, C. G., Torlone, E., Scionti, L., Perriello, G., & Bolli, G. B. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01323.x · Cited by 129
Dalziel, K., Round, A., Stein, K., Garside, R., & Price, A. (2004) · Health Technology Assessment · doi:10.3310/hta8280 · Cited by 127
Schober, Ε., Schoenle, Ε., Van Dyk, J., Wernicke-Panten, Κ., & Pediatric Study Group of Insulin Gl (2002) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2002.15.4.369 · Cited by 121
Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01781.x · Cited by 118
Tricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., Harrington, A., Wilson, C., Tsouros, S., Soobiah, C., et al. (2014) · BMJ · doi:10.1136/bmj.g5459 · Cited by 117
Pieber, T. R., Draeger, E., Kristensen, A., & Grill, V. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01545.x · Cited by 117
Kølendorf, K., Ross, G. P., Pavlic‐Renar, I., Perriello, G., Philotheou, A., Jendle, J., Gall, M., & Heller, S. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01862.x · Cited by 108
Pedersen‐Bjergaard, U., Kristensen, P. L., Beck‐Nielsen, H., Nørgaard, K., Perrild, H., Christiansen, J. S., Jensen, T. J., Hougaard, P., Parving, H., Thorsteinsson, B., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70073-7 · Cited by 103
Rys, P., Wojciechowski, P., Rogoz-Sitek, A., Niesyczyński, G., Lis, J., Syta, A., & Malecki, M. T. (2015) · Acta Diabetologica · doi:10.1007/s00592-014-0698-4 · Cited by 101
Linnebjerg, H., Lam, E. C. Q., Seger, M. E., Coutant, D., Chua, L., Chong, C. L., Ferreira, M. M., Soon, D., & Zhang, X. (2015) · Diabetes Care · doi:10.2337/dc14-2623 · Cited by 94
Standl, E., Lang, H., & Roberts, A. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.579 · Cited by 92
Gomes, M. B., Coral, M. H. C., Cobas, R. A., Dib, S. A., Canani, L. H. S., Nery, M., Foss‐Freitas, M. C., Faria, M. D. S., Felício, J. S., da Silva, S. C., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.008 · Cited by 91
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
Warren, E., Weatherley-Jones, E., Chilcott, J. B., & Beverley, C. (2004) · Health Technology Assessment · doi:10.3310/hta8450 · Cited by 89
Fulcher, G. R., Gilbert, R. E., & Yue, D. K. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2005.00902.x · Cited by 77
Insulin Analogs—Are They Worth It? Yes!
Grunberger, G. (2014) · Diabetes Care · doi:10.2337/dc14-0031 · Cited by 77
Rosenstock, J., Park, G., & Zimmerman, J. (2001) · Clinical Diabetology · Cited by 74
Home, P. D., Rosskamp, R., Forjanic-Klapproth, J., Dressler, A., & (on behalf of the European Insulin Glargine Study Group) (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.572 · Cited by 68
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Rotenstein, L. S., Ran, N. A., Shivers, J. P., Yarchoan, M. M., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.138 · Cited by 61
de Souza, A. L. C., Acúrcio, F. D. A., Guerra, A. A., do Nascimento, R. C. R. M., Godman, B., & Diniz, L. M. (2014) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0073-6 · Cited by 60
Rebuttal to editorial saying cancer survival statistics are misleading
Coleman, M. P., Rachet, B., Woods, L., Berrino, F., Butler, J., Capocaccia, R., Dickman, P., Gavin, A., Giorgi, R., Hamilton, W., et al. (2011) · BMJ · doi:10.1136/bmj.d4214 · Cited by 56
Chase, H. P., Arslanian, S. A., White, N. H., & Tamborlane, W. V. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.04.063 · Cited by 56
Intermediate acting versus long acting insulin for type 1 diabetes mellitus
Vardi, M., Jacobson, E., Nini, A., & Bitterman, H. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006297.pub2 · Cited by 53
Chatterjee, S., Jarvis-Kay, J., Rengarajan, T., Lawrence, I. G., McNally, P. G., & Davies, M. J. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.11.002 · Cited by 51
Bolli, G. B., Songini, M., Trovati, M., Prato, S. D., Ghirlanda, G., Cordera, R., Trevisan, R., Riccardi, G., & Noacco, C. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.05.003 · Cited by 51
Danne, T., Philotheou, A., Goldman, D., Guo, X., Ping, L., Cali, A., & Johnston, P. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12051 · Cited by 48
Frier, B. M., Russell‐Jones, D., & Heise, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12106 · Cited by 46
Insulin analogues in children with Type 1 diabetes: a 52‐week randomized clinical trial
Thalange, N., Bereket, A., Larsen, J., Hiort, L. C., & Peterkova, V. (2013) · Diabetic Medicine · doi:10.1111/dme.12041 · Cited by 41
Hassan, K., Rodríguez, L. M., Johnson, S. E., Tadlock, S., & Heptulla, R. A. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1679 · Cited by 38
Gabriel, E. E., & Gilbert, P. B. (2013) · Biostatistics · doi:10.1093/biostatistics/kxt055 · Cited by 37
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, J., & White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597915 · Cited by 36
Heinemann, L. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815605337 · Cited by 35
Dżygało, K., Golicki, D., Kowalska, A., & Szypowska, A. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0604-0 · Cited by 35
Tran, K., Banerjee, S., Li, H., Cimon, K., Daneman, D., Simpson, S. H., & Campbell, K. (2007) · Cited by 28
Szypowska, A., Golicki, D., Groele, L., & Pańkowska, E. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1065 · Cited by 25
Esposito, K., Chiodini, P., Capuano, A., Petrizzo, M., Improta, M. R., & Giugliano, D. (2012) · Diabetes Care · doi:10.2337/dc12-0698 · Cited by 25
Doničová, V., Brož, J., & Sorin, I. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500513 · Cited by 24
Sanches, A. C. C., Correr, C. J., Venson, R., & Pontarolo, R. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.001 · Cited by 23
Sanches, A. C. C., Correr, C. J., Venson, R., Gonçalves, P. R., Garcia, M. M., Piantavini, M. S., & Pontarolo, R. (2013) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502013000300011 · Cited by 19
Tsujino, D., Nishimura, R., Onda, Y., Seo, C., Ando, K., Morimoto, A., & Utsunomiya, K. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0167-z · Cited by 18
Do the benefits of analog insulins justify their costs?
Holden, S. E., & Currie, C. J. (2012) · Diabetes Management · doi:10.2217/dmt.12.17 · Cited by 6
Mianowska, B., Szadkowska, A., Czerniawska, E., Pietrzak, I., & Bodalski, J. (2007) · PubMed · Cited by 4
Biosimilar insulins: current and future perspectives
Krentz, A. J., & Hompesch, M. (2015) · Diabetes Management · doi:10.2217/dmt.15.33 · Cited by 3
Dawoud, D., Fenu, E., Wonderling, D. E., O’Mahony, R., Pursey, N. A., Cobb, J. K., Amiel, S., & Higgins, B. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.136 · Cited by 2
Godman, B., de Souza, A. L. C., Acúrcio, F. D. A., & Guerra, A. A. (2014) · Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) · Cited by 1
Research works printed but not linked: 10
- T William, 2016, American Diabetes Association standards of medical care in diabetes 2016, Diabetes Care, 39, S1
- A Szypowska, 2009, Better metabolic control, less hypoglycemia and less weight gain with insulin detemir versus NPH insulin in intensive insulin therapy for patients with type 1 diabetes. A meta-analysis, Diabetologia, 52, S387
- P Rossetti, 2003, Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime, Diabetes Care, 26, 1490, 10.2337/diacare.26.5.1490 · DOI · Paper page
- P Home, 2004, Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial, Diabetes Care, 27, 1081, 10.2337/diacare.27.5.1081 · DOI · Paper page
- P Home, 2003, Insulin detemir offers improved glycemic control, less weight gain, and flexible timing of administration compared to NPH insulin, Diabetes, 52, A122
- JD Russell, 2004, Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen, Clin Ther, 26, 724, 10.1016/s0149-2918(04)90072-0 · DOI · Paper page
- PC Bartley, 2008, Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial, Diabet Med, 25, 442, 10.1111/j.1464-5491.2007.02407.x · DOI · Paper page
- SL Bowker, 2005, Systematic review of indicators and measurements used in controlled studies of quality improvement for type 2 diabetes, Can J Diabetes, 29, 230
- DM Nathan, 2014, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview, Diabetes care, 37, 9, 10.2337/dc13-2112 · DOI · Paper page
- RM Bergenstal, 2015, No difference in Major Adverse Cardiovascular Events (MACE plus) with Basal Insulin peglispro (BIL) vs comparator insulins in patients with type 1 or type 2 diabetes, Diabetologia, 58, S65
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
“Rapid-acting insulin analogs (lispro, glulisine, or aspart) and long-acting insulin analogs (glargine, detemir, or degludec) should be used first in patients with T1DM when treated with MDIs (RCT, General) [14,56-61].”
BackgroundHypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 154
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Lind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Metadata
- Authors
- Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G.
- Affiliations
- Universidade de Brasília (BR)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-04-12
- Volume
- 13
- Issue
- 4
- Pages
- e0194801
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5896894
- OpenAlex
- W2796961649
- Cited by
- 41
- References
- 83
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 12 · 2020: 6 · 2019: 12
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Americanae (AECID Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- RIUnB Institutional Repository (University of Brasília) (submittedVersion, cc-by)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Ministério da Educação
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- long-acting insulin analogues, type 1 diabetes, insulin glargine, insulin detemir, NPH insulin, HbA1c, hypoglycemia, nocturnal hypoglycemia, severe hypoglycemia, insulin therapy comparison
- MeSH terms
- Insulin Glargine, Insulin Detemir, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Regression Analysis, Models, Statistical, Randomized Controlled Trials as Topic, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.